FLT3 and acute myeloid leukemia: Sorafenib is a potent inhibitor of VEGFR, KIT, PDGFR (platelet-derived growth factor receptor) and FLT3; the latter of which is mutated in 25–30% of AML cases, causing a constitutively active variant and promoting leukemogenesis (119).